Loomis, Sayles & Company
ANIP icon

Loomis, Sayles & Company’s ANI Pharmaceuticals ANIP Stock Holding History

Loomis, Sayles & Company’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Sell
162,792
-194
-0.1% -$15.6K 0.02% 335
2026
Q1 		$12.5M Sell
162,986
-5,843
-3% -$456K 0.02% 315
2025
Q4 		$13.3M Sell
168,829
-3,314
-2% -$287K 0.02% 307
2025
Q3 		$15.8M Sell
172,143
-34,239
-17% -$2.79M 0.02% 277
2025
Q2 		$13.5M Buy
206,382
+12,494
+6% +$813K 0.02% 311
2025
Q1 		$13M Sell
193,888
-297
-0.2% -$17.7K 0.02% 307
2024
Q4 		$10.7M Buy
194,185
+19,568
+11% +$1.12M 0.01% 358
2024
Q3 		$10.4M Sell
174,617
-6,831
-4% -$417K 0.01% 353
2024
Q2 		$11.6M Buy
181,448
+1,105
+0.6% +$71.7K 0.02% 338
2024
Q1 		$12.5M Sell
180,343
-86
-0% -$5.19K 0.02% 324
2023
Q4 		$9.95M Buy
180,429
+15,200
+9% +$837K 0.02% 336
2023
Q3 		$9.59M Sell
165,229
-3,426
-2% -$198K 0.02% 340
2023
Q2 		$9.08M Buy
168,655
+64,643
+62% +$2.87M 0.01% 355
2023
Q1 		$4.13M Buy
+104,012
New +$4.39M 0.01% 408
2018
Q4 		– Sell
-108
Closed -$6K – 843
2018
Q3 		$6K Hold
108
– – ﹤0.01% 870
2018
Q2 		$7K Hold
108
– – ﹤0.01% 848
2018
Q1 		$6K Hold
108
– – ﹤0.01% 853
2017
Q4 		$7K Sell
108
-300
-74% -$18.7K ﹤0.01% 813
2017
Q3 		$21K Buy
408
+31
+8% +$1.48K ﹤0.01% 755
2017
Q2 		$18K Buy
377
+256
+212% +$12.3K ﹤0.01% 767
2017
Q1 		$6K Buy
121
+18
+17% +$1.01K ﹤0.01% 850
2016
Q4 		$6K Hold
103
– – ﹤0.01% 883
2016
Q3 		$7K Hold
103
– – ﹤0.01% 818
2016
Q2 		$6K Sell
103
-24
-19% -$1.17K ﹤0.01% 812
2016
Q1 		$4K Sell
127
-119
-48% -$4.04K ﹤0.01% 948
2015
Q4 		$11K Buy
+246
New +$10.6K ﹤0.01% 846

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company's ANIP Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its ANI Pharmaceuticals (ANIP) stake by 0.12% in Q2 2026, selling an estimated $15.6K and leaving 162,792 shares worth $13.5M. The position accounts for 0.02% of the portfolio, ranked #335.

Loomis, Sayles & Company first reported a position in ANIP in Q4 2015 and has held it in 26 quarters since. The position peaked at $15.8M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Loomis, Sayles & Company held 162,792 shares of ANI Pharmaceuticals worth $13.5M as of Q2 2026.
  • Loomis, Sayles & Company sold 194 ANI Pharmaceuticals shares in Q2 2026, an estimated $15.6K.
  • ANI Pharmaceuticals made up 0.02% of Loomis, Sayles & Company's portfolio in Q2 2026, its #335 holding.
  • Loomis, Sayles & Company first reported a position in ANI Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
  • Loomis, Sayles & Company's ANI Pharmaceuticals position peaked at $15.8M in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.